

- of methicillin resistant staphylococcus aureus in a tertiary referral hospital in eastern Uttar Pradesh. *Indian Journal of Medical Microbiology* 2003; 21: 49-51.
3. **Wattal C, Goel N, Oberoi JK, Prasad KJ, Datta S, Raveendran R.** *Microbiology newsletter. Sir Ganga Ram Hospital: volume 15 (1), 2009. Available from: http://www.sgrh.com.*
 4. **Reinert RR, Low DE, Rossi F, Zhang X, Wattal C and Dowzicky MJ.** Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TESTand the in vitro activity of tigecycline. *Journal of Antimicrobial Chemotherapy* 2007 doi:10.1093/jac/dkm310:1-12)
 5. **Conterno LO, Wey SB, Castelo A.** Risk factors for mortality in Staphylococcus aureus bacteremia. *Infect Control Hosp Epidemiol* 1998; 19:32-37.
 6. **Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E.** Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak. *Ann Intern Med.* 1982;96:11-16.
 7. **Raghunath D.** Molecular characterization of Indian Methicillin-resistant S.aureus. *Antimicrobial Resistance- The Modern Epidemic. Volume 9 Macmillan publishers p 167-184.*
 8. **Song JH, Hsueh PR, Ko KS, et al.** Emergence of multidrug-resistant community associated methicillin-resistant Staphylococcus aureus in Asian countries (submitted)
 9. **Diep BA, Carleton HA, Chang RF, Sensabaugh GF,2 and Remington FP.** Roles of 34 Virulence Genes in the Evolution of Hospital- and Community-Associated Strains of Methicillin-Resistant Staphylococcus aureus. *JID* 2006; 193: 1495-1503
 10. **Thomas R, Wallin, Gene H,Bradley W, Frazee, MD.** Community-Associated Methicillin-Resistant Staphylococcus aureus. *Emerg Med Clin N Am* 2008;26:431-455
 11. **Herold BC, Immergluck LC, Maranan LC, et al.** Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. *JAMA* 1998; 279:593-8.
 12. **Song JH.** Global emergence of community associated MRSA : An update. *ISAAR* 2009.
 13. **Lina G, Piemont Y, Godail-Gamot F, et al.** Involvement of Panton- Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. *Clin Infect Dis.* 1999;29:1128-1132.
 14. **Gauduchon V, Cozon G, Vandenesch F, et al.** Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. *J Infect Dis.* 2004;189:346-353.
 15. **Liassine N, Auckenthaler R, Descombes MC, Bes M, Vandenesch F, Etienne J.** Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. *J Clin Microbiol.* 2004;42:825-828.
 16. **Diederer BM, Kluytmans JA.** The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. *J Infect* 2006; 52:157-168.
 17. **Miller LG, Perdreau-Remington F, Rieg G, et al.** Necrotizing Fasciitis Caused by Community-AssociatedMethicillin-Resistant Staphylococcus aureus in Los Angeles. *N Engl JMed* 2005;352:1445-53.
 18. **Fraze BW, Salz TO, Lambert L, et al.** Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia in an immunocompetent young adult. *Ann Emerg Med* 2005;46:401-4.
 19. **gorwitz RJ, Jernigan DB, Powers JH, et al.** Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006.
 20. **Micek ST, DunneM, KollefMH.** Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. *Chest* 2005;128:2732-8.
 21. **Scheetz MH,Wunderink RG, Postelnick MJ, et al.** Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. *Pharmacotherapy* 2006;26:539-50.
 22. **Seybold U, Kourbatova EV, Johnson JG et al.** Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 genotype as a major cause of health care-associated blood stream infections. *Clin Infect Dis* 2006; 42:647-66.
 23. **Huang H, Flynn NM, King JH, Monchaud C, Morita M, and Cohen SH.** Comparisons of Community-Associated Methicillin-ResistantStaphylococcus aureus (MRSA) and Hospital-AssociatedMRSRA Infections in Sacramento, California. *Journal of Clinical Microbiology* 2006;44(7) :2423-2427

DRUG PROFILE

Trospium Chloride

Indications and Usage: Trospium is an anticholinergic drug, indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. **Dosage and Administration:** The recommended dose is 20mg twice daily. The drug should be given with water on an empty stomach, at least one hour before the meal. **Contraindications:** The drug is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions. **Warning and precautions:** The drug should be administered with caution to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders due to risk of urinary or gastric retention. In patients with narrow angle glaucoma, it should be used only with careful monitoring. The drug is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/Min). Alcohol should not be consumed within 2hrs of administration, of the drug. **Adverse reactions:** These include dry mouth (10.7%) and constipation (8.5%). **Drug Interactions:** Trospium is metabolized by ester hydrolysis and is excreted by kidneys through tubular secretion and glomerular filtration. Concomitant use with digoxin did not effect the pharmacokinetics of either drug. The oral bioavailability was reduced following a high fat-content meal. **Use in specific population: Pregnancy:** Use not advisable, drug is excreted to a limited extent into the milk; avoid in lactating mothers. **Pediatric :** The safety and effectiveness of the drug in Pediatric patients have not been established. **Renal Impairment:** Trospium is not recommended for use in patients with moderate to severe renal impairment. Caution is advised when the drug is used in patients with severe hepatic impairment.

CONFERENCE NEWS

ASICON 2010: 70th Annual Conference Association of Surgeons of India Theme: Showcasing Indian Surgery
17th - 22nd, December 2010, Venue: New Delhi



For Details Contact :

Prof. Sandip Mukherjee
Organising Chairman

Dr. Arvind Kumar
Organising Secretary

Room No. 5010C, Teaching Block, All India Institute of Medical Sciences, Anasi Nagar, New Delhi-110029, India
Phone: 011-26593460, 26588259 Fax: 011-26588259 Email: info@asicon2010.org Website: www.asicon2010.org